Virus

LANDSEA HOMES LAUNCHES HIGH PERFORMANCE HOME PROGRAM IN COLORADO; CELEBRATES GRAND OPENINGS FOR TWO NEW COMMUNITIES

Retrieved on: 
Monday, April 8, 2024
Highlands Preserve, Apple, REME, Partnership, Geek Squad, Carbon footprint, Acquisition, Bacteria, Virus, Dander, Dust, House, Thermostat, Pollen, Sustainability, Lighting, LED, Health

*

Key Points: 
  • *
    The company's notable homes merge design, technology, and sustainability to promote energy savings and a healthy lifestyle.
  • Landsea Homes entered the Colorado housing market last October via the acquisition of Richfield Homes.
  • All of Landsea Homes' High Performance Homes are supported by a partnership with Apple®, the homes utilize the Apple HomeKit™ environment to operate all home automation features from one mobile application.
  • For more information about Landsea Homes' High Performance Home program, visit https://landseahomes.com/hph .

Philips GoPure GP5212 Automotive Air Purifier Removes up to 90% of Airborne Pollen Inside Vehicles

Retrieved on: 
Friday, April 5, 2024
Filter (signal processing), Gas, HESA, Bacteria, Virus, SO2, Particulates, Dust, Pollen, Multimedia, Air pollution, NO2, SUV, HEPA, Allergen

FARMINGTON HILLS, Mich., April 5, 2024 /PRNewswire/ -- Lumileds, a leading lighting solutions company, offers the Philips GoPure GP5212 Automotive Air Purifier for those who suffer from seasonal allergies. Powerful, compact, and simple to use, GoPure GP5212 effectively filters out airborne allergens including pollen and mold that can pass through the cabin filters typically found in vehicles. Standard cabin air filters typically trap particulates of 5-100 microns. The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases. The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.

Key Points: 
  • The Philips GoPure GP5212 can filter particles as small as .015 microns, including allergens, viruses, and bacteria, as well as toxic gases.
  • The advanced filtering of the GoPure GP5212 helps trap pollen, keeping it out of the eyes and airways of vehicle occupants.
  • Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions.
  • "The new Phillips GoPure GP5212 car air purifier meets a growing demand for clean air solutions," noted Aubry Baugh, Lumileds Sr.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

Retrieved on: 
Saturday, March 23, 2024
Clinical research associate, District court, Patient, Research, Ext, LLP, Viral, News, Virus, Complaint, Pomerantz, Action Replay, Court, Person

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

CHECKLIGHT® from CISO Global Proven to Reduce Cyber Loss, According to 2023 Measurement Data

Retrieved on: 
Tuesday, March 19, 2024
SMB, Algorithm, Federation, Research, CISO, Virus, Insurance, EDR, Behavior, Machine learning, Cryptocurrency

Scottsdale, Ariz., March 19, 2024 (GLOBE NEWSWIRE) -- CISO Global (NASDAQCM: CISO), an industry leader as a managed cybersecurity and compliance provider, successfully tested the effectiveness of its CHECKLIGHT® Endpoint Detection and Response (EDR) solution under strenuous and highly targeted environments over the past year. Through actuarial data collection, CISO Global found that it significantly reduced the number and severity of cyber losses to the very low single digits for users of the technology.

Key Points: 
  • Through actuarial data collection, CISO Global found that it significantly reduced the number and severity of cyber losses to the very low single digits for users of the technology.
  • CHECKLIGHT® continuously scans for fraudulent phishing attacks, hacking, imposter scams, malware, ransomware, and viruses.
  • CHECKLIGHT® was developed in part to address this gap estimated to represent $80 billion in cyber protection for the North American SMB market.
  • For those companies pursuing cyber insurance, CHECKLIGHT®’s continuous monitoring capabilities help them meet requirements for cyber insurance eligibility.

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

Retrieved on: 
Monday, March 18, 2024
District court, Patient, Defendant, Research, News, Viral, Virus, Complaint, Action Replay, Court, Advertising, Security (finance)

If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.

Key Points: 
  • If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

Retrieved on: 
Friday, March 15, 2024
Prior, Clinical research associate, District court, Patient, Research, Ext, LLP, Viral, News, Virus, Complaint, Pomerantz, Action Replay, Court, Person

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Retrieved on: 
Wednesday, March 13, 2024
CD4, PDSB, Infection, Patent, Influenza, Research, Virus, Biotechnology, Antibody, Intellectual property, Use, Viral, Vaccine

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune®.

Key Points: 
  • The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.
  • Infectimune® is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains.
  • The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
  • “Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy.”

Global Microbiome Manufacturing Markets 2023-2024 & 2035: Industry Trends, Forecasts, Formulation, Primary Packaging Used, Scale of Operation, Company Size, Key Regions and Leading Developers - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Vitamins, Supplements, Neurology, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, General Health, Pharmaceutical, Health, Clostridioides difficile infection, Type, Organization, Database, AOBiome, Microbiota, Patient, CNS, CGMP, Research, Fungus, FDF, Bacteria, Virus, Laboratory, Overalls, Infection, DSM-IV codes, API, Safety, Phase, Therapy, USD, LBP

Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.

Key Points: 
  • Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.
  • Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies.
  • This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Pharmaceutical, Health, Disease, Smallpox, Virus, Mpox, Viral disease, Infection, CDC, Bavarian Nordic, Family, FDA, Pharmaceutical industry

Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.

Key Points: 
  • Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.
  • As the only FDA-approved mpox vaccine, JYNNEOS is now commercially available in the U.S., marking a significant expansion for access.
  • Bavarian Nordic announced its commercial entry into the US on April 2, noting the ongoing need for the vaccine.
  • “We are proud to be a key partner in expanding access to this first-to-market vaccine,” says Layne Martin, head of Specialty at Morris & Dickson.

Cal-Maine Foods, Inc. Reports Positive Test Result for Avian Influenza at Texas Facility

Retrieved on: 
Tuesday, April 2, 2024
Infectious Diseases, Supermarket, Restaurant, Bar, Food, Beverage, Health, Retail, Agriculture, Supply Chain Management, Natural Resources, USDA, Season, APHIS, Risk, Virus, Security (finance), HPAI, CALM

Production at the facility has temporarily ceased as the Company follows the protocols prescribed by the USDA.

Key Points: 
  • Production at the facility has temporarily ceased as the Company follows the protocols prescribed by the USDA.
  • Cal-Maine Foods is working to secure production from other facilities to minimize disruption to its customers.
  • The Company remains dedicated to robust biosecurity programs across its locations; however, no farm is immune from HPAI.
  • The APHIS division of the USDA and individual states track and publicly report individual incidents of HPAI by location.